Three Regulators, One Warning: Why Health Authorities Worldwide Are Targeting Unregulated Peptides
Three separate health authorities, including the Dutch inspectorate and Health Canada, issued warnings on grey-market peptides within months of each other.
By UAE Peptide Clinic Research Desk
When one regulator warns about a product, it can be dismissed as local caution. When three regulators on two continents reach the same conclusion within a few months, using different evidence, it is worth paying attention. That is what happened with grey-market peptides in 2026.
The Netherlands: you do not know what you are getting
In February 2026 the Dutch Health and Youth Care Inspectorate (IGJ) issued a public warning about peptides sold online for weight loss, muscle growth and recovery. As reported by NL Times, the inspectorate's message was blunt: buyers of these products simply do not know what they are getting. The IGJ pointed out that products marketed as research chemicals are not medicines in any legal sense, are not checked for content or sterility, and are being injected by people with no medical supervision. The inspectorate noted that it was seeing growing numbers of these products advertised on social media to young adults.
Canada: a court injunction and a plain-language advisory
Health Canada went further than a warning. In 2026 it obtained a court injunction against Canlab Research, an online seller of unauthorised peptides, and published an advisory urging consumers to think twice before buying peptides online. The advisory stressed that unauthorised injectables may contain the wrong ingredient, the wrong dose or harmful contaminants, and that no Canadian authority had assessed them for safety, quality or effectiveness. Reporting in The Washington Post the same year described US state medical boards grappling with the same problem, as clinics and sellers blurred the line between research chemicals and prescription medicines.
Three different legal systems, three different sets of inspectors, one identical finding: unregulated peptides cannot be trusted.
United States: the ECRI and ISMP white paper
In May 2026 ECRI, an independent patient-safety organisation, and the Institute for Safe Medication Practices published a white paper on unregulated peptides. It is the most clinically detailed of the three documents, and its findings deserve a list of their own.
- Purity of tested research-chemical peptides ranged from as low as 5% to around 75%, against the 98% or higher expected of a pharmaceutical product.
- Samples were found to contain heavy metals including arsenic and lead.
- For BPC-157, one of the most popular grey-market peptides, 35 of 36 studies reviewed were animal studies; human evidence was almost absent.
- A clinical trial of one marketed peptide had been halted after a fatal cardiac event, a fact rarely mentioned by sellers.
- Rita Jew, president of ISMP, warned that consumers were treating untested compounds as if they were approved medicines.
Why the findings converge
The three bodies did not coordinate. They looked at different sellers, in different countries, and applied different laws. They converged because the underlying problem is structural. A product sold outside the medicines system has no mandatory testing, no inspected manufacturing, no cold chain, no accountable prescriber and no recall mechanism. Every regulator who looks finds the same gaps because the gaps are built in.
How the UAE fits in
The UAE reached the same conclusion through its own evidence. In August 2026 the Emirates Drug Establishment acted against 71 online sellers and 14 influencers promoting unregistered peptide injections, with UAE physicians describing patients who had self-injected unknown products. The direction of travel is the same everywhere: peptides are moving firmly into the category of prescription medicine, where they belong.
For patients, that is good news. It means that where a peptide is clinically appropriate, it can be prescribed by an independent licensed physician, dispensed by a licensed pharmacy and monitored over time. It also means the products sold on Telegram are being pushed out of the market rather than into your fridge.
The practical takeaway
Whether any peptide is appropriate for you is a decision for a licensed physician. If no licensed physician will prescribe it, that is information, not an obstacle to route around. You can read how physician-led prescribing works at /how-we-work.
Sources
- NL Times, 15 February 2026: Dutch Health and Youth Care Inspectorate (IGJ) warning on peptides sold online.
- Health Canada, 2026: court injunction against Canlab Research and public advisory on unauthorised peptides.
- The Washington Post, 2026: reporting on US state medical board oversight of peptide sellers and clinics.
- ECRI and the Institute for Safe Medication Practices, 5 May 2026: white paper on the risks of unregulated peptides.
- Khaleej Times, 3 August 2026: Emirates Drug Establishment action against 71 online peptide sellers and 14 influencers.
If you want to understand whether any of this is relevant to you, an independent DHA-licensed physician can review your case. Take the two-minute quiz at /find-my-stack or book a physician consultation at /book (AED 300 deposit, credited to your first order).
